Xytos Inc. (fka XYTS)

[breezin_chs]

Any thoughts, guesses, opinions?

XYTOS UPDATE TO SHAREHOLDERS

CARSON CITY, NV.-- (OTC NEWS DISCLOSURE SERVICE) -- Dec. 7, 2010 -- XYTOS, Inc. (the "Company") (OTC: XYTS) is pleased to announce that after years spent working on our Bio-Medical Technology the company is ready to move forward. For several years XYTOS has worked to put all the necessary pieces in place to insure that the company moves forward on a solid foundation. During this formation period the company remained silent with very limited news announcements. Additionally, with the loss of our last Chief Medical Officer the company was delayed in getting started with the treatment of Cancer Patients in the United States. After an extensive search XYTOS announced the appointment of the company's New Chief Medical Officer, Dr. John Trotter II, MD. Since the Appointment of Doctor Trotter, the company has moved quickly to position itself to start treating patients in the United States with other geographical areas to be announced. With XYTOS now in a position to start treatments, management has made it a priority to bring the company to a fully reporting status. XYTOS has now started the discloser process and has completed the first steps of disclosure. The company will soon be filing additional disclosure information to bring the company to a fully reporting status. Additionally, the company has structured the stock in a manner to avoid dilution to the shareholders. In an effort to protect the existing shareholders and the strength of the stock in the future, the company has not issued any additional free trading shares since the original registration, more than 10 years ago. The company was required to issue Non-Tradable Restricted Shares to secure the Bio-Medical Technology that the company now controls. The Non-Tradable Restricted Shares WILL NOT be available to trade in the Stock Market. Currently there are 31,268,000 outstanding shares and approximately half of these shares are Restricted and Non-Tradable. Additionally, the company will be updating the website and announcing additional Bio-Medical Technologies that will be in addition to what the company already controls. The Company will follow up with additional news announcements to keep the shareholders updated as the company starts treating patients.

Tim Cook, Chairman and CEO of XYTOS, Inc., commented, “We are truly excited to finally be moving forward. We have limited the news that we have put out and we have limited our disclosures until we had the approvals in place to treat and the Doctors ready to start treating patients. We now have the necessary foundation in place to insure that XYTOS becomes a Global Leader in Advanced Medicine”.

XYTOS, working at the forefront of the "Science of Medicine," is a Bio-Medical Technologies Company concentrating on the research, development, and introduction of Next Generation Medicine and Medical Procedures in the areas of Stem Cell Therapies, Tissue Engineering, Cellular Medicine, and Cancer.

On behalf of the Board of Directors of: XYTOS Inc.

Tim Cook, CEO (Contact: [e-mail])

Telephone: [phone]